Secondary Logo

Journal Logo

This month’s editor’s favorite is Sanli and colleagues’ “225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer”. The pairing of the alpha emitter 225Ac to PSMA therapy for prostate cancer is appealing. The authors present their preliminary results with 225Ac-PSMA therapy in 12 patients with advanced stage metastatic castration-resistant prostate cancer.
Patients were treated with 225Ac-PSMA therapy every 8 weeks, and prostate-specific antigen (PSA) response was analyzed. Overall survival (OS) and progression-free survival (PFS) were estimated. Hematological and nonhematological adverse effects were recorded before and at 8 weeks after the last treatment cycle.
In total, 25 cycles of 225Ac-PSMA were administered to the 12 patients. Pretreatment median PSA level was 129 ng/mL. After the first cycle, PSA responses were observed in 9 of 12 patients. Six had biochemical response of >50%. Four of 12 patients reached the best PSA response after the first treatment cycle, whereas 3 patients responded more after the second and 2 patients after the third cycle. Median PFS and OS were 4 and 10 months, respectively. For patients with any PSA response after the first cycle, OS was improved but without statistical significance (10 vs 4 months; P = 0.301) when compared with the nonresponsive group. No significant difference was encountered in terms of adverse effect in the pretreatment and posttreatment era.
These preliminary results are encouraging, especially patients who had PSA response after the first cycle of 225Ac-PSMA therapy.​

Current Issue


Key Role of Personalized Dosimetry in Dose Adjustment for Selective Internal Radiotherapy: Retrospective Study of Patients Treated With 90Y Resin Microspheres

Subreville, Celine; Pinaquy, Jean-Baptiste; Lapuyade, Bruno; More

Clinical Nuclear Medicine. 46(12):958-964, December 2021.

Dual-Time-Point 18F-Fluorocholine PET/CT Improves Characterization of Thyroid Nodules in Patients Referred for Primary Hyperparathyroidism: A Proof of Concept Study

Bani, Jacob; Morland, David; Hubelé, Fabrice; More

Clinical Nuclear Medicine. 46(12):965-970, December 2021.



Show: